232 related articles for article (PubMed ID: 36175917)
1. A randomized, double-blind, placebo-controlled, hybrid parallel-arm study of low-dose naltrexone as an adjunctive anti-inflammatory treatment for major depressive disorder.
Plank JR; Glover SC; Moloney BD; Hoeh NR; Sundram F; Sumner RL; Muthukumaraswamy S; Lin JC
Trials; 2022 Sep; 23(1):822. PubMed ID: 36175917
[TBL] [Abstract][Full Text] [Related]
2. No evidence for clinical efficacy of adjunctive celecoxib with vortioxetine in the treatment of depression: A 6-week double-blind placebo controlled randomized trial.
Baune BT; Sampson E; Louise J; Hori H; Schubert KO; Clark SR; Mills NT; Fourrier C
Eur Neuropsychopharmacol; 2021 Dec; 53():34-46. PubMed ID: 34375789
[TBL] [Abstract][Full Text] [Related]
3. Randomized, proof-of-concept trial of low dose naltrexone for patients with breakthrough symptoms of major depressive disorder on antidepressants.
Mischoulon D; Hylek L; Yeung AS; Clain AJ; Baer L; Cusin C; Ionescu DF; Alpert JE; Soskin DP; Fava M
J Affect Disord; 2017 Jan; 208():6-14. PubMed ID: 27736689
[TBL] [Abstract][Full Text] [Related]
4. Anti-inflammatory treatment of depression: study protocol for a randomised controlled trial of vortioxetine augmented with celecoxib or placebo.
Fourrier C; Sampson E; Mills NT; Baune BT
Trials; 2018 Aug; 19(1):447. PubMed ID: 30126458
[TBL] [Abstract][Full Text] [Related]
5. Low-dose naltrexone for the treatment of fibromyalgia: protocol for a double-blind, randomized, placebo-controlled trial.
Bruun KD; Amris K; Vaegter HB; Blichfeldt-Eckhardt MR; Holsgaard-Larsen A; Christensen R; Toft P
Trials; 2021 Nov; 22(1):804. PubMed ID: 34781989
[TBL] [Abstract][Full Text] [Related]
6. Youth Depression Alleviation with Anti-inflammatory Agents (YoDA-A): a randomised clinical trial of rosuvastatin and aspirin.
Berk M; Mohebbi M; Dean OM; Cotton SM; Chanen AM; Dodd S; Ratheesh A; Amminger GP; Phelan M; Weller A; Mackinnon A; Giorlando F; Baird S; Incerti L; Brodie RE; Ferguson NO; Rice S; Schäfer MR; Mullen E; Hetrick S; Kerr M; Harrigan SM; Quinn AL; Mazza C; McGorry P; Davey CG
BMC Med; 2020 Jan; 18(1):16. PubMed ID: 31948461
[TBL] [Abstract][Full Text] [Related]
7. A randomised, double-blind, active placebo-controlled, parallel groups, dose-response study of scopolamine hydrobromide (4-6 μg/kg) in patients with major depressive disorder.
Chen JCC; Sumner RL; Krishnamurthy Naga V; Hoeh N; Ayeni HA; Singh V; Sundram F; Campbell D; Muthukumaraswamy S
Trials; 2020 Feb; 21(1):157. PubMed ID: 32041658
[TBL] [Abstract][Full Text] [Related]
8. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract][Full Text] [Related]
9. Youth Depression Alleviation-Augmentation with an anti-inflammatory agent (YoDA-A): protocol and rationale for a placebo-controlled randomized trial of rosuvastatin and aspirin.
Quinn AL; Dean OM; Davey CG; Kerr M; Harrigan SM; Cotton SM; Chanen AM; Dodd S; Ratheesh A; Amminger GP; Phelan M; Williams A; Mackinnon A; Giorlando F; Baird S; Rice S; O'Shea M; Schäfer MR; Mullen E; Hetrick S; McGorry P; Berk M
Early Interv Psychiatry; 2018 Feb; 12(1):45-54. PubMed ID: 26542332
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of eicosapentaenoic acid in inflammatory depression: study protocol for a match-mismatch trial.
Suneson K; Ängeby F; Lindahl J; Söderberg G; Tjernberg J; Lindqvist D
BMC Psychiatry; 2022 Dec; 22(1):801. PubMed ID: 36536364
[TBL] [Abstract][Full Text] [Related]
11. N-acetylcysteine as add-on to antidepressant medication in therapy refractory major depressive disorder patients with increased inflammatory activity: study protocol of a double-blind randomized placebo-controlled trial.
Yang C; Bosker FJ; Li J; Schoevers RA
BMC Psychiatry; 2018 Sep; 18(1):279. PubMed ID: 30176835
[TBL] [Abstract][Full Text] [Related]
12. Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies.
Tourian KA; Padmanabhan SK; Groark J; Brisard C; Farrington D
Clin Ther; 2009 Jun; 31 Pt 1():1405-23. PubMed ID: 19698901
[TBL] [Abstract][Full Text] [Related]
13. Simvastatin add-on to escitalopram in patients with comorbid obesity and major depression (SIMCODE): study protocol of a multicentre, randomised, double-blind, placebo-controlled trial.
Otte C; Chae WR; Nowacki J; Kaczmarczyk M; Piber D; Roepke S; Märschenz S; Lischewski S; Schmidt S; Ettrich B; Grabe HJ; Hegerl U; Hinkelmann K; Hofmann T; Janowitz D; Junghanns K; Kahl KG; Klein JP; Krueger THC; Leicht G; Prvulovic D; Reif A; Schoettle D; Strauss M; Westermair A; Friede T; Gold SM
BMJ Open; 2020 Dec; 10(12):e040119. PubMed ID: 33262189
[TBL] [Abstract][Full Text] [Related]
14. Nutritional counselling in adults promoting adherence to the Mediterranean diet as adjuvant in the treatment of major depressive disorder (INDEPT): a randomized open controlled trial study protocol.
Sousa-Santos N; Fialho M; Madeira T; Clara C; Veiga S; Martins R; Barros N; Santos G; Santos O; Almeida C; Ganança L; Campos RC; Camolas J; da Silva AP; Guarino MPS; Heitor MJ
BMC Psychiatry; 2023 Apr; 23(1):227. PubMed ID: 37016319
[TBL] [Abstract][Full Text] [Related]
15. Evidence for Anti-inflammatory Effects of Adalimumab in Treatment of Patients With Major Depressive Disorder: A Pilot, Randomized, Controlled Trial.
Abbasian F; Bagheri S; Moradi K; Keykhaei M; Etemadi A; Shalbafan M; Shariati B; Vaseghi S; Samsami FS; Akhondzadeh S
Clin Neuropharmacol; 2022 Sep-Oct 01; 45(5):128-134. PubMed ID: 36093920
[TBL] [Abstract][Full Text] [Related]
16. Low dose naltrexone for induction of remission in Crohn's disease.
Segal D; Macdonald JK; Chande N
Cochrane Database Syst Rev; 2014 Feb; (2):CD010410. PubMed ID: 24558033
[TBL] [Abstract][Full Text] [Related]
17. Study protocol for a randomised, double-blinded, placebo-controlled phase III trial examining the add-on efficacy, cost-utility and neurobiological effects of low-dose naltrexone (LDN) in patients with fibromyalgia (INNOVA study).
Colomer-Carbonell A; Sanabria-Mazo JP; Hernández-Negrín H; Borràs X; Suso-Ribera C; García-Palacios A; Muchart J; Munuera J; D'Amico F; Maes M; Younger JW; Feliu-Soler A; Rozadilla-Sacanell A; Luciano JV
BMJ Open; 2022 Jan; 12(1):e055351. PubMed ID: 34992118
[TBL] [Abstract][Full Text] [Related]
18. Add-on Treatment with Curcumin Has Antidepressive Effects in Thai Patients with Major Depression: Results of a Randomized Double-Blind Placebo-Controlled Study.
Kanchanatawan B; Tangwongchai S; Sughondhabhirom A; Suppapitiporn S; Hemrunrojn S; Carvalho AF; Maes M
Neurotox Res; 2018 Apr; 33(3):621-633. PubMed ID: 29327213
[TBL] [Abstract][Full Text] [Related]
19. Low dose naltrexone for induction of remission in Crohn's disease.
Parker CE; Nguyen TM; Segal D; MacDonald JK; Chande N
Cochrane Database Syst Rev; 2018 Apr; 4(4):CD010410. PubMed ID: 29607497
[TBL] [Abstract][Full Text] [Related]
20. A Randomized, Double-Blind, Placebo-Controlled, Sequential Parallel Comparison Design Trial of Adjunctive Riluzole for Treatment-Resistant Major Depressive Disorder.
Mathew SJ; Gueorguieva R; Brandt C; Fava M; Sanacora G
Neuropsychopharmacology; 2017 Dec; 42(13):2567-2574. PubMed ID: 28553836
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
